Coherus Oncology (CHRS) Income from Continuing Operations (2013 - 2026)

Coherus Oncology has disclosed Income from Continuing Operations across 14 years of filings, most recently posting 36935000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 36935000.0, up 22.07% year-over-year; the trailing twelve-month figure through Mar 2026 was 172661000.0 (up 11.88% YoY), and the FY2025 annual result was 183124000.0, up 14.98% from the prior year.
• Income from Continuing Operations came in at 36935000.0 for Q1 2026 at Coherus Oncology, up from 46347000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 36935000.0 in Q1 2026 to a low of 96084000.0 in Q1 2022.
• The 5-year median for Income from Continuing Operations is 47599000.0 (2024), against an average of 56840235.29.
• Across the five-year window, Income from Continuing Operations plunged 124.9% in 2022 and soared 54.25% in 2023, its largest moves.
• Coherus Oncology's Income from Continuing Operations stood at 58870000.0 in 2022, then plunged by 35.3% to 79653000.0 in 2023, then soared by 42.13% to 46093000.0 in 2024, then dropped by 0.55% to 46347000.0 in 2025, then rose by 20.31% to 36935000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 36935000.0 (Q1 2026), 46347000.0 (Q4 2025), and 44517000.0 (Q3 2025), per Business Quant data.